本帖最后由 老马 于 2013-3-13 13:43 编辑 ' _, G. u7 |" m4 Q* q
+ P. r: w& `* d: w3 c
健择(吉西他滨)+顺铂+阿瓦斯汀" j9 r8 A1 ?. c! K# q
Gemzar +Cisplatin + Avastin+ V; Y, O9 \( b% w& P$ @* [
http://annonc.oxfordjournals.org/content/21/9/1804.full
0 s% g1 S! q* ^: m( B, JOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) c% L- G8 }$ A7 E
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, b7 \! N, X: OResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 G* n6 C3 F5 I) [# r
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 206)
) J4 `7 F C; K3 h) z! |
华为网盘附件:
4 `* w! |8 P6 Y! \4 X- \+ r* M8 y# l【华为网盘】ava.JPG
( [6 ~& C; {$ w) ?, F |